Summit Therapeutics Inc. Current Liabilities
Summit Therapeutics Inc. (SMMT) had Current Liabilities of $103.57 million as of 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-07-23
- 2026-06-30: Liabilities, Current $103.57M.
- 2026-03-31: Liabilities, Current $83.27M.
- 2025-12-31: Liabilities, Current $72.99M.
- 2025-09-30: Liabilities, Current $64.93M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $103.57M 10-Q · filed 2026-07-23 |
| 2026-03-31 | $83.27M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $72.99M 10-Q · filed 2026-07-23 |
| 2025-09-30 | $64.93M 10-Q · filed 2025-10-20 |
| 2025-06-30 | $60.33M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $34.88M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $41.73M 10-K · filed 2026-02-23 |
| 2024-09-30 | $59.01M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $140.17M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $23.44M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $20.41M 10-K · filed 2025-02-24 |
| 2023-09-30 | $113.74M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $11.93M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $17.44M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $38.78M 10-K · filed 2024-02-20 |
| 2022-09-30 | $16.68M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $15.17M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $22.72M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $25.62M 10-K · filed 2023-03-09 |
| 2021-09-30 | $22.79M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $21.89M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $73.05M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $19.89M 10-K/A · filed 2022-12-21 |
| 2020-09-30 | $14.74M 10-Q · filed 2020-11-16 |
| 2020-06-30 | $13.20M 8-K · filed 2020-09-29 |
| 2019-12-31 | $13.77M 10-K · filed 2021-03-31 |
| 2019-01-31 | $17.18M 8-K · filed 2020-09-29 |
| 2018-01-31 | $32.58M 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |